In addition, the reactivation of endogenous p53 has the potential to enhance the sensitivity of cervical cancer (CC) cells to radiotherapy or chemotherapy (specifically, cisplatin + vincristine + bleomycin), as demonstrated in studies [66,67] Consequently, the reactivation of p53 has emerged as one of the most promising strategies for the effective treatment of cervical cancer in HIV patients [63,68]. Here, TP53 is linked to cervical cancer.